TY - JOUR
T1 - Autoderm
T2 - An alternative bioprosthetic for breast reconstruction
AU - Selber, Jesse C.
AU - Clemens, Mark W.
AU - Oates, Scott
AU - Baumann, Donald P.
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2013/5
Y1 - 2013/5
N2 - SUMMARY:: The widespread use of bioprosthetic mesh in breast reconstruction has revealed an increased risk of seroma and infection, and a high financial cost. This study introduces a technique that mitigates these shortcomings using an autologous dermal graft (Autoderm). Indications, operative technique, and 1-year outcomes are reviewed. Thirty-six breasts in 21 patients underwent six unilateral and 15 bilateral, implant-based breast reconstructions with Autoderm. Mean follow-up was 365 days (range, 273 to 575 days). The overall complication rate was 13.9 percent. No patients developed breast cellulitis, hyperemia, periprosthetic infection, or seroma. There was one implant exposure following expansion. Autoderm provides the advantages of lower pole support and breast shaping, without the disadvantages of increased infection, seroma, and the high cost associated with allograft and xenograft meshes. CLINICAL QUESTION/LEVEL OF EVIDENCE:: Therapeutic, IV.
AB - SUMMARY:: The widespread use of bioprosthetic mesh in breast reconstruction has revealed an increased risk of seroma and infection, and a high financial cost. This study introduces a technique that mitigates these shortcomings using an autologous dermal graft (Autoderm). Indications, operative technique, and 1-year outcomes are reviewed. Thirty-six breasts in 21 patients underwent six unilateral and 15 bilateral, implant-based breast reconstructions with Autoderm. Mean follow-up was 365 days (range, 273 to 575 days). The overall complication rate was 13.9 percent. No patients developed breast cellulitis, hyperemia, periprosthetic infection, or seroma. There was one implant exposure following expansion. Autoderm provides the advantages of lower pole support and breast shaping, without the disadvantages of increased infection, seroma, and the high cost associated with allograft and xenograft meshes. CLINICAL QUESTION/LEVEL OF EVIDENCE:: Therapeutic, IV.
UR - http://www.scopus.com/inward/record.url?scp=84877758242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877758242&partnerID=8YFLogxK
U2 - 10.1097/PRS.0b013e3182865af3
DO - 10.1097/PRS.0b013e3182865af3
M3 - Article
C2 - 23629080
AN - SCOPUS:84877758242
SN - 0032-1052
VL - 131
SP - 985
EP - 987
JO - Plastic and reconstructive surgery
JF - Plastic and reconstructive surgery
IS - 5
ER -